• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Agilent Revolutionizes HPLC with the Launch of the Agilent Infinity III LC Series

    10/21/24 2:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Elevating lab efficiency with enhanced automation, connectivity, and sustainability capabilities

    Agilent Technologies Inc. (NYSE:A) today announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions. These are the first HPLC systems on the market to feature the new Agilent InfinityLab Assist Technology, offering enhanced, built-in system assistance capabilities. This technology allows labs to focus more on achieving results rather than on daily operation and maintenance tasks.

    With the introduction of these new LC systems, Agilent is revolutionizing the LC user experience. These systems significantly enhance task automation, connectivity, predictive feedback, and error reduction. The innovative built-in sample tracking, utilizing barcoding and camera technologies ensures the elimination of sample mix-ups, providing users with greater accuracy and peace of mind.

    The incorporation of the new InfinityLab Assist is designed to enhance the on-board capabilities of the LC for all users. It supports analysts of all skill levels by automating instrument routines, simplifying sample preparation, assisting with maintenance and troubleshooting, and providing context-sensitive help content and solvent management guidance. These features will transform the user experience by eliminating repetitive and error-prone manual tasks, reducing the time required for training and onboarding, and delivering greater robustness and instrument insights that strengthen confidence in the results.

    "Analytical lab managers face intense pressure to optimize operational efficiency without sacrificing result quality. With InfinityLab Assist, our customers can significantly reduce the time and effort spent on operator training, troubleshooting, and automating daily startup routines and system health notifications," said Sudharshana Seshadri, vice president and general manager of Agilent's Liquid Chromatography, Mass Spectrometry, and Automation divisions. "While the three new LC families fully incorporate the InfinityLab Assist Technology, we continue to offer modularity and upgradeability to support our installed base, both now and in the future, to safeguard existing investments as new InfinityLab Assist features are added over time."

    Additionally, the instruments in the new Infinity III LC Series feature method compatibility with earlier LC systems and seamless chromatography data systems (CDS) integration. The new systems feature third-party verification by My Green Lab's revised ACT 2.0 Ecolabel, a global standard for assessing the environmental impact of laboratory equipment and supplies. They will also be the first LC systems to provide their CO2 footprint to customers, demonstrating Agilent's commitment to environmental sustainability. It is also noteworthy that all new features are available as upgrades to the existing Infinity II LC Series, representing an outstanding level of investment protection.

    "Collectively, the instruments in the Infinity III LC Series establish a new benchmark in liquid chromatography," said Philip Binns, president of Agilent's Life Sciences and Applied Markets group. "Agilent is committed to exceeding user expectations by delivering intelligent instrumentation that simplify operations and enhance productivity. Our customers can look forward to a future with seamless system integration, minimal downtime, and consistently reliable results. Today's release marks a significant milestone in our journey of continuous innovation, and we are excited to continue pushing the boundaries of LC technology."

    With the introduction of these next-generation LC systems, Agilent reinforces its market position as a leading provider of innovative and differentiated analytical solutions that elevate the laboratory experience and materially grow return-on-investment opportunities.

    The launch of the new Agilent Infinity III LC Series will take place simultaneously across the globe in October including HPLC 2024, Dalian, China, AAPS 2024 PharmSci 360, US, and 23rd Human Proteome Organization World Congress (HUPO), Germany.

    About Agilent Technologies

    Agilent Technologies Inc., (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241020073645/en/

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What new product has Agilent Technologies announced?

      Agilent Technologies has launched the new InfinityLab LC Series portfolio to enhance lab efficiency through automation and connectivity.

    • What is the purpose of the InfinityLab Assist Technology introduced by Agilent?

      The InfinityLab Assist Technology automates tasks, simplifies sample preparation, and provides maintenance assistance, enhancing user experience.

    • What are some key features of the new Infinity III LC Series systems?

      Agilent's new systems provide advanced automation capabilities, help eliminate sample mix-ups, and sustain environmental standards through Ecolabel verification.

    • How does the Infinity III LC Series support existing users of Agilent's products?

      The Infinity III LC Series offers method compatibility with earlier versions and is designed to protect existing investments while integrating new features.

    • What is the financial and employment status of Agilent Technologies as mentioned in the announcement?

      Agilent achieved $6.83 billion in revenue in fiscal 2023 and employs approximately 18,000 people worldwide, reinforcing its market leadership.

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy
    HSBC Securities
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    12/9/2025$170.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    10/8/2025$165.00Buy
    Rothschild & Co Redburn
    10/8/2025$170.00Neutral → Buy
    UBS
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00

    1/5/26 8:23:48 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Equal Weight to Overweight and set a new price target of $165.00

    12/15/25 8:55:45 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rataj Sue H.

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    3/23/26 4:39:21 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Brawley Otis W

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    3/23/26 4:36:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Scangos George A

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    3/23/26 4:29:59 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

    Test enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. (NYSE:A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indicated to identify patients with esophageal or GEJ carcinoma whose tumors express PD-L1 (Combined Positive Score

    3/26/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

    Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice Agilent Technologies Inc. (NYSE:A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundation for scalable, automation‑ready pathology laboratories. At USCAP 2026, Agilent will feature its continued expansion in oncology

    3/19/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

    Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions. Agilent Advanced Therapeutics' CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides cus

    3/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Agilent Technologies Inc.

    SCHEDULE 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    3/26/26 3:12:29 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/20/26 4:05:09 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/6/26 4:05:24 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Financials

    Live finance-specific insights

    View All

    Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

    Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t

    2/25/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    2/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    7/22/24 9:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials